NCT03041636View on ClinicalTrials.gov

Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 8, 2017

Primary Completion Date

April 29, 2020

Study Completion Date

April 29, 2020

Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaUntreated Chronic Lymphocytic Leukemia
Interventions
DRUG

Ruxolitinib

Given PO

DRUG

Ruxolitinib Phosphate

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03041636 - Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Biotech Hunter | Biotech Hunter